Pharmaceutical companies are expressing uncertainty after former President Donald Trump proposed a 200% tariff on generic drugs, according to a report. The proposal includes a two-year window before the tariff takes effect, giving manufacturers time to adjust. The move is aimed at reducing reliance on foreign-made generics, especially from countries like India, which is a major supplier. Generic drugs are cheaper alternatives to brand-name medicines and are widely used in the United States. If implemented, the tariff could significantly increase costs for American patients and healthcare providers. Industry analysts say the two-year window may allow companies to shift production or negotiate, but the high tariff rate poses a serious challenge. Many generic drug makers operate on thin margins and may struggle to absorb the added cost. The proposal comes amid broader trade tensions and efforts to boost domestic manufacturing. However, critics argue that the tariff could lead to drug shortages and higher prices. The pharmaceutical industry is closely watching developments as the proposal moves through the legislative process. A final decision has not been made, and the details of the plan could change. For now, companies are assessing the potential impact on their supply chains and pricing strategies. The uncertainty has already affected stock prices of some generic drug manufacturers.